Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells.
説明 | VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. |
分子量 | 449.57 |
分子式 | C25H27N3O3S |
CAS No. | 228544-65-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (133.46 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VULM 1457 228544-65-8 Metabolism Acyltransferase acyl-CoA:cholesterol acyltransferase hypercholesterolaemia Diacylglycerol acyltransferase ischaemia-reperfusion myocardial Diglyceride acyltransferase mono- acylglycerol acyltransferase Inhibitor acyl-CoA VULM-1457 cholesterol acyltransferase VULM1457 hypolipidaemic inhibit diabetes mellitus inhibitor